Details of Drug-Drug Interaction
| Drug General Information (ID: DDI4LHNDF9) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Lansoprazole | Drug Info | Nilotinib | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Proton Pump Inhibitors | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Lansoprazole-Nilotinib Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hypomagnesemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Lansoprazole | Nilotinib | |||||||
| Mechanism | Hypomagnesemia | Hypomagnesemia | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hypomagnesemia | ||||||||
| Factor Description | Hypomagnesemia is a condition that occurs when you have too much magnesium in your body. Symptoms of hypomagnesemia include: nausea, vomiting, neurological damage, abnormally low blood pressure (hypotension), flushing, and headaches. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The concomitant use of proton pump inhibitors should generally be avoided during therapy with nilotinib. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||||||||||||||||